1-cyano-2-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-5-methyl-benzene | 1022984-20-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyano-2-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-5-methyl-benzene
• 英文别名: 2-[(4-ethylphenyl)methyl]-5-methyl-4-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]benzonitrile
• CAS: 1022984-20-8
• 化学式: C₂₃H₂₇NO₅
• 分子量: 397.471
• InChiKey: AACOGWZOMPLOCZ-ZQGJOIPISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  114
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  1-bromo-2-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-5-methylbenzene 、 氰化镍 以 N-甲基吡咯烷酮 为溶剂， 反应 1.0h， 以85%的产率得到1-cyano-2-(4-ethylbenzyl)-4-(β-D-glucopyranos-1-yl)-5-methyl-benzene
  参考文献：
  名称：

  WO2008/55870

  摘要：

  公开号：

文献信息

• PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATIVE
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3939577A1

  公开（公告）日：2022-01-19

  The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  该发明涉及根据权利要求1的药物组合物，包括一种葡萄糖吡喃基取代苯衍生物与一种适用于治疗或预防从以下选定的一种或多种疾病的DPP IV抑制剂的组合物，所述疾病包括1型糖尿病、2型糖尿病、糖耐量受损和高血糖。此外，本发明涉及预防或治疗代谢紊乱及相关疾病的方法。
• GLUCOPYRANOSYL-SUBSTITUTED BENZYL-BENZONITRILE DERIVATES, MEDICAMENTS CONTAINING SUCH COMPOUNDS, THEIR USE AND PROCESS FOR THEIR MANUFACTURE
  申请人：Himmelsbach Frank

  公开号：US20100069310A1

  公开（公告）日：2010-03-18

  Glucopyranosyl-substituted benzyl-benzonitrile derivatives of general formula (I) as defined according to claim 1 , including the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.

  通式(I)中含有葡萄糖吡喃基取代的苯基苯甲腈衍生物，如权利要求1所定义，包括其互变异构体、立体异构体、混合物和盐。本发明的化合物适用于治疗代谢性疾病。
• PHARMACEUTICAL COMPOSITION COMPRISING A GLUCOPYRANOSYL-SUBSTITUTED BENZENE DERIVATE
  申请人：Dugi Klaus

  公开号：US20110195917A1

  公开（公告）日：2011-08-11

  The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  该发明涉及一种药物组合物，根据权利要求1，包括一种葡萄糖吡喃基取代的苯衍生物和一种适用于治疗或预防从以下选择的一种或多种疾病的DPP IV抑制剂：1型糖尿病，2型糖尿病，糖耐量受损和高血糖。此外，本发明还涉及预防或治疗代谢紊乱和相关疾病的方法。
• Methods for preventing and treating neurodegenerative disorders
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2382972A1

  公开（公告）日：2011-11-02

  The present invention relates to a method for treating, preventing or slowing, delaying or reversing progression of one or more neurodegenerative disorders in a patient in need thereof characterized by administering a glucopyranosyl-substituted benzene derivative, a tautomer, stereoisomer, mixture or salt thereof, as defined in claim 1 to the patient in need thereof.

  本发明涉及一种治疗、预防或减缓、延迟或逆转有需要的患者的一种或多种神经退行性疾病进展的方法，其特征在于向有需要的患者施用权利要求1中定义的葡萄糖吡喃糖基取代的苯衍生物、其同分异构体、立体异构体、混合物或盐。
• Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivative
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2698152A1

  公开（公告）日：2014-02-19

  The invention relates to a pharmaceutical composition according to the claim 1 comprising a glucopyranosyl-substituted benzene derivative in combination with a DPP IV inhibitor which is suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance and hyperglycemia. In addition the present invention relates to methods for preventing or treating of metabolic disorders and related conditions.

  本发明涉及根据权利要求1所述的药物组合物，该药物组合物由葡糖吡喃糖基取代的苯衍生物与DPP IV抑制剂组合而成，适用于治疗或预防选自1型糖尿病、2型糖尿病、糖耐量受损和高血糖症的一种或多种病症。此外，本发明还涉及预防或治疗代谢紊乱及相关疾病的方法。